Ozempic and GLP-1 Face: What to Do About Facial Volume Loss on GLP-1 Medication
Written and medically reviewed by Dr Muhammad Nadim, M.Biomed — Regenerative Medicine, SŌMA Aesthetics & Longevity Club, Uluwatu · Published 15 October 2026 · Last reviewed 15 October 2026
The short answer: "Ozempic face" is not a side effect of the medicine in the usual sense. It is what a face looks like when fat is lost quickly from the compartments that give it shape, often in skin that no longer has the collagen to shrink back neatly. The most reliable fix is staged rather than instant: protect muscle and avoid losing weight faster than necessary; improve skin quality and collagen while weight is still coming off; restore structural volume conservatively once weight has been stable for a few months; and treat any remaining skin laxity on its own terms. Simply adding more filler is rarely the whole answer.
Key takeaways
The changes come from fat loss, not from a toxic effect of the drug, and they occur with any GLP-1 medication — semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) — and with rapid weight loss generally.
Imaging research shows the midface loses roughly 7% of its volume for every 10 kg of body weight lost, mostly from the superficial fat pads.
Volume, skin quality and skin laxity are three different problems, and each needs a different treatment.
Skin-quality and collagen-stimulating treatments can start during weight loss; structural filler is best placed once weight has plateaued.
Protein intake, resistance training and sun protection influence how the face ages through weight loss as much as any injectable does.
Why GLP-1 patients are asking about their faces
Most patients who arrive at SŌMA with this question are pleased with their medication. Their blood results have improved, their clothes fit differently and they feel well. What they did not expect was to look more tired, older or gaunt in photographs — and they want to know what can be done without undoing the progress they have made.
They are far from alone. In the American Society of Plastic Surgeons' 2025 member survey, 82% of surgeons reported receiving consultation requests related to GLP-1 medication, and the society noted that "a larger percentage of patients are interested in addressing facial volume loss." The American Academy of Facial Plastic and Reconstructive Surgery's 2025 survey found that 67% of its members had seen more patients seeking treatment linked to rapid weight loss, alongside a second consecutive year of 50% growth in facial fat grafting. A recent review in Dermatologic Surgery acknowledged that the popular label is imprecise but describes "a real clinical observation".
What actually happens to the face during GLP-1 weight loss
The face is not a single layer of fat. It contains a series of separate fat compartments — some just beneath the skin, others deeper against bone and muscle — that give the temples, cheeks and under-eye area their fullness and keep the transitions between them smooth. When these compartments shrink, the effects are recognisable: hollow temples, flatter cheeks, more visible under-eye hollows, deeper folds from nose to mouth, and a softer jawline as the skin envelope becomes slightly too large for what lies beneath it.
The first objective measurement of this came from Vanderbilt University Medical Center in 2025. Researchers compared CT and MRI scans taken before and after patients started GLP-1 medication. Across 20 patients who lost an average of 11 kg over roughly 321 days, total midfacial volume fell by a median of 9%. Superficial fat lost more (about 11%) than deep fat (about 7%, with wide variation between individuals), and the team estimated a loss of roughly 7% of midfacial volume for every 10 kg of total body weight lost.
Three other factors shape how visible those changes become:
Skin quality and age. From the mid-twenties onwards, collagen and elastin decline steadily. Younger skin tends to contract after weight loss; older or sun-damaged skin is less able to, which is why the same weight loss can look very different at 30 and at 55.
Muscle. In the STEP 1 trial body-composition substudy, participants on semaglutide 2.4 mg lost about 15% of their body weight, and around 39% of the weight lost was classed as lean mass on DXA scanning. Lean mass includes water and organ tissue as well as muscle, so the true muscle share is smaller — but the finding is a strong argument for adequate protein and resistance training during treatment.
Possible effects on skin cells. Early laboratory work, summarised in reviews published in Endocrine (2025) and Aesthetic Surgery Journal (2024), has raised the possibility that GLP-1 receptors on fat-derived stem cells and skin fibroblasts could influence skin quality directly. This remains a hypothesis rather than an established effect in people, but it reinforces the case for treating skin quality, not just volume.
In Bali there is a fourth factor: ultraviolet exposure. Sun damage breaks down the same collagen that helps skin adapt to volume loss, so daily broad-spectrum protection is part of any plan.
Who is most likely to notice Ozempic face?
Not everyone on a GLP-1 medication develops visible facial changes. The risk is higher with:
Age from the late thirties onwards, when collagen reserves and skin elasticity are lower.
Large or fast weight loss, particularly more than about 10% of body weight, or weight coming off quickly in the first months of treatment.
A naturally lean or narrow face, which has less fat to lose before hollowing shows.
Sun damage or smoking history, both of which weaken the collagen that helps skin adapt.
Low protein intake and no resistance training, which increase the loss of lean tissue alongside fat.
Previous large weight swings, which tend to leave skin with less capacity to contract.
Signs of Ozempic face
The changes usually appear gradually over the first few months of treatment and are most visible in photographs taken in flat light. The common signs are:
hollowing at the temples and a more visible bony outline around the eyes
flatter cheeks and loss of the soft curve beneath the cheekbones
deeper under-eye hollows and a tired look, sometimes called "Ozempic eyes"
deeper lines running from the nose to the mouth and from the mouth to the chin
a softer jawline and early jowls
looser, more crepey skin on the neck
skin that looks thinner and duller overall
Should treatment wait until the weight loss is finished?
This is the most common question in consultation, and the evidence supports a split answer depending on the layer being treated.
Skin quality and collagen stimulation can begin during active weight loss. These treatments strengthen the skin itself rather than filling space, so they do not need a stable endpoint. A recent paper in the Journal of Cosmetic Dermatology cites a clinical report in which early treatment with diluted calcium hydroxylapatite helped preserve mid- and lower-face volume in GLP-1 patients who were losing weight quickly.
Structural volume is best restored once weight has plateaued. Placing hyaluronic acid filler into a face that is still shrinking means chasing a moving target. As a general guide, SŌMA's doctors prefer weight to have been stable for around three to six months before restoring structural volume, so that the result fits the face the patient will actually live with.
Skin laxity is assessed last. Some tightening occurs naturally as skin quality improves and volume is restored, so energy-based tightening or lifting is planned once the other layers have been addressed.
How to reduce the risk while taking a GLP-1
Facial change cannot always be prevented, but it can be reduced. The measures with the most support are practical rather than cosmetic:
Lose weight at a steady pace. As a general guide, losing more than about 1% of body weight per week over several months makes it harder to preserve lean tissue. Dose and pace are worth discussing with the prescribing doctor rather than pushing for the fastest possible result.
Eat enough protein. Adults losing weight are commonly advised to aim for roughly 1.2–1.6 g of protein per kilogram of body weight per day, spread across meals. Appetite suppression makes this harder than it sounds, so it often needs planning.
Do resistance training at least two or three times a week. Strength work is the most reliable way to protect muscle during weight loss.
Stay hydrated. Dehydration makes skin look thinner and lines look deeper, and reduced appetite often means reduced fluid intake too.
Protect the skin from the sun every day. Broad-spectrum SPF 50, a hat and shade at midday matter more in Bali than almost anywhere else.
Start skin-quality treatments early if the risk factors above apply, rather than waiting until the change is obvious.
Patients on SŌMA's medical weight management programme have their body composition measured during treatment, which shows whether weight is coming from fat or from muscle and allows the plan to be adjusted early.
A layer-by-layer approach to restoring the face
Each concern below has its own treatment page with full details, pricing and FAQs. The loss of volume and sagging jowls guide compares the options side by side.
What the patient notices | What is happening | Treatments that address it |
|---|---|---|
Hollow temples, flat cheeks, under-eye hollows | Loss of structural volume | Dermal fillers; PRF bio-filler made from the patient's own blood |
A thinner, less firm face overall | Diffuse fat and collagen loss | Collagen bio-stimulators such as calcium hydroxylapatite and PLLA-based products |
Crepey, dull or dehydrated skin | Declining skin quality | Skin boosters, including hyaluronic acid and polynucleotide treatments |
A softer jawline, early jowls, loose neck skin | Skin laxity and descended tissue | XERF skin tightening; thread lifting for tissue that has dropped |
Fatigue, slower progress, worries about muscle | Body composition and metabolic health | Doctor-supervised weight management with medical body-composition analysis and blood tests |
The distinction between fillers and bio-stimulators matters. Hyaluronic acid fillers give an immediate, reversible result in a specific area. Bio-stimulators work more slowly, prompting the skin to build its own collagen over three to six months, and cannot be dissolved — which is why they are dosed conservatively and reviewed before more is added. Many GLP-1 patients benefit from both: bio-stimulators to rebuild the foundation, followed by small, precise amounts of filler where structure is missing.
Are dermal fillers enough to fix Ozempic face?
Sometimes, but not usually on their own. For a small, well-defined hollow — at the temples or under the cheekbones, for example — in someone whose weight is stable and whose skin is in good condition, hyaluronic acid filler alone can give a natural result, and it has the advantage of being reversible with hyaluronidase.
For most GLP-1 patients, however, volume has been lost across the whole face and the skin itself has become thinner. Filler used to correct every area tends either to under-correct or to look heavy. The more reliable pattern is a foundation of collagen stimulation, followed by small amounts of dermal filler placed where structure is genuinely missing, alongside skin-quality treatment. Where volume loss is severe, surgical options such as fat grafting or a facelift may be more appropriate, and a referral is the honest recommendation.
Ozempic face in men
Men are affected too, and often notice it first at the temples and along the jaw. The aim of treatment is different: restoring a defined jawline, chin and temple contour keeps the face looking strong and lean, whereas adding cheek fullness can feminise it. SŌMA's aesthetic treatments for men are planned with that structure in mind.
Does Ozempic face go away on its own?
Generally, no. Stopping the medication does not reverse the change, and weight that is regained does not return evenly — it often goes to the body before the face. Collagen and skin elasticity lost during rapid weight loss do not recover simply because weight increases, and regaining weight would undo the metabolic benefits of treatment. Younger patients with mild changes may see some improvement over several months as the skin adapts, but for most people the change is best treated rather than waited out. The encouraging part is that it responds well to a staged, layer-by-layer plan.
Common mistakes to avoid
Replacing all lost volume with filler. Volume loss after weight loss is diffuse, and trying to refill it point by point with filler is the usual route to a heavy, overfilled look.
Placing large amounts of structural filler mid-loss. A result that looks right at month three of treatment may look misplaced by month nine.
Losing weight faster than necessary. Rapid loss, low protein intake and no resistance training increase the loss of muscle and make facial changes more pronounced. Dose and pace are worth discussing with the prescribing doctor.
Ignoring the sun. UV damage undoes collagen work, and Bali's UV index is high year-round.
Expecting injectables to solve heavy excess skin. Non-surgical treatments work well for mild to moderate change. Where there is substantial loose skin, a surgical opinion is the honest recommendation, and SŌMA's doctors will say so.
What a consultation at SŌMA covers
A GLP-1 facial consultation at SŌMA starts with the medication history — which drug, the current dose, when treatment started, total weight lost and whether weight is still falling. The doctor then assesses the face layer by layer (volume, skin quality and laxity), takes standardised photographs and, where useful, recommends body-composition analysis to check muscle mass. The outcome is a staged plan. For visitors to Bali, that often means starting skin-quality and collagen work on one trip and completing structural restoration on the next, as results from bio-stimulators build over months rather than days.
"Most patients are delighted with their weight loss. What they want is to look as healthy as they feel. The answer is rarely more filler — it is rebuilding the right layers in the right order." — Dr Muhammad Nadim, M.Biomed
Frequently asked questions
What is Ozempic or GPL-1 face?
Ozempic face is an informal term for the hollowing, sagging and older appearance some people notice after rapid weight loss on GLP-1 medications such as Ozempic, Wegovy or Mounjaro. It is caused mainly by loss of facial fat, combined with skin that cannot contract fully.
Does Ozempic face go away after stopping the medication?
Not reliably. Some volume may return if weight is regained, but not necessarily in the same places, and skin laxity does not resolve on its own. Regaining weight is not a recommended treatment.
Can Ozempic face be prevented?
It can be reduced, though not always prevented. Avoiding unnecessarily rapid weight loss, eating enough protein, doing resistance training, protecting the skin from the sun and starting skin-quality treatments early all help.
How long after starting a GLP-1 can I have fillers?
Skin-quality and collagen-stimulating treatments can be done during weight loss. Structural hyaluronic acid filler is best placed once weight has been stable for around three to six months.
Are fillers or bio-stimulators better for Ozempic face?
They do different jobs. Bio-stimulators rebuild collagen across the face over several months, while fillers restore volume precisely and immediately. Most patients do best with a combination planned by a doctor.
Does only Ozempic cause Ozempic face?
No. The same changes can follow any significant, rapid weight loss, whether from semaglutide, tirzepatide, bariatric surgery or diet.
Can I have aesthetic injectables while taking a GLP-1?
In most cases, yes. The treating doctor needs to know the medication, dose and weight-loss history so the plan accounts for a face that may still be changing.
Is Mounjaro face different from Ozempic face?
No. "Mounjaro face" describes the same changes in people losing weight on tirzepatide. Because tirzepatide often produces greater weight loss, the facial changes can be more noticeable, but the causes and treatments are the same.
What are Ozempic eyes?
"Ozempic eyes" is an informal term for hollowing under and around the eyes after rapid weight loss, which can make the eyes look sunken and tired. It is usually treated as part of the wider face, with skin-quality treatment and, where suitable, carefully placed filler.
Patients on GLP-1 medication who would like a facial assessment can contact SŌMA on WhatsApp at +62 811 2522 8000. The clinic in Uluwatu is open daily from 9:00 to 20:00.
This article is general information and does not replace a medical consultation. Treatment suitability is assessed individually by a doctor.
References
Sharma RK, Vittetoe KL, Barna AJ, et al. Radiographic midfacial volume changes in patients on GLP-1 agonists. Otolaryngology–Head and Neck Surgery. 2025;173(2):360–366.
American Society of Plastic Surgeons. The GLP-1 effect: from body to face and what happens next (2026).
American Academy of Facial Plastic and Reconstructive Surgery. 2025 annual survey findings, reported by Modern Aesthetics.
GLP-1–induced weight loss and the face: anatomical mechanisms and rationale for collagen-stimulating and volumizing aesthetic treatments. Dermatologic Surgery.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989–1002 — body-composition substudy abstract.
McCarthy et al. Rising public interest in weight loss medications and growing awareness of their aesthetic sequelae. Journal of Cosmetic Dermatology. 2026.
Paschou IA, et al. GLP-1 receptor agonists and the possible skin aging. Endocrine. 2025;89(3):680–685.
Ridha Z, et al. Aesthetic Surgery Journal. 2024;44(11):NP809–NP818.
